Diabetes Mellitus: A Comprehensive Overview of Clinical, Pharmacological and Technological Advances

[1]Tanushri Popat Gawande, [2]Mrs. Snehal Trimbak Daud, [3]Dr. D.K. Vir, [4]Dipali Pandhrinath Khillare, [5]Vaishnavi Kachru Ghuge.

1) Student, 2) Associate professor,3) Principal, 4)Student, 5) Student

Department of Pharmaceutical Science and Technology.

Shree Goraksha College of Pharmacy & Research Centre, Chhatrapati Sambhaji Nagar, India

Abstract- Diabetes mellitus (DM) is a chronic metabolic disorder marked by persistent hyperglycemia due to impaired insulin secretion, action, or both. Its global prevalence is rising rapidly, currently affecting over half a billion individuals, and it is a major contributor to cardiovascular, renal, and neurological complications. DM is classified mainly into type 1, type 2, and gestational diabetes, each with distinct pathophysiological mechanisms. Early diagnosis and effective management are crucial to prevent long-term complications. Current therapeutic strategies include lifestyle interventions, oral hypoglycemic agents, and insulin therapy. Recent advances have introduced novel approaches such as nanotechnology-based drug delivery systems, stem cell therapy, and gene-targeted interventions, offering promising prospects for improved glycemic control and disease modification. This review provides an updated overview of the types, pathophysiology, diagnosis, management strategies, and emerging therapies for DM, emphasizing innovations that may shape future clinical practice and enhance patient outcomes.

Keywords: Diabetes Mellitus, Hyperglycemia, Insulin Resistance, Nanotechnology, Stem Cell Therapy, Gene-Based Therapy

1. Introduction

Diabetes mellitus (DM) is a chronic and multifactorial metabolic disorder characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. This dysregulation disrupts normal carbohydrate, lipid, and protein metabolism, leading to various systemic complications over time. DM is broadly classified into Type 1 diabetes mellitus (T1DM), caused by autoimmune-mediated destruction of pancreatic β-cells, and Type 2 diabetes mellitus (T2DM), resulting from insulin resistance and relative insulin deficiency. Other less common forms include gestational diabetes and monogenic diabetes syndromes.

The pathophysiology of diabetes is complex, involving genetic, environmental, and lifestyle factors. Chronic hyperglycemia induces vascular and cellular damage through mechanisms such as oxidative stress, inflammation, and the accumulation of advanced glycation end-products (AGEs), ultimately contributing to long-term complications. These complications include diabetic retinopathy, nephropathy, neuropathy, cardiovascular diseases, and peripheral vascular disease, which significantly impair quality of life and increase morbidity and mortality rates.

Epidemiologically, diabetes has reached pandemic proportions. According to the International Diabetes Federation (IDF), approximately 537 million adults were living with diabetes in 2021, a number projected to rise to 783 million by 2045. The global surge in diabetes prevalence is largely driven by increasing rates of obesity, sedentary lifestyles, unhealthy dietary habits, and urbanization. T2DM accounts for over 90% of all diabetes cases worldwide and is strongly associated with lifestyle and environmental factors.

Early diagnosis and effective management of diabetes are crucial for preventing complications. Lifestyle interventions such as regular physical activity, dietary modifications, and weight management, alongside pharmacological therapies, play a pivotal role in controlling blood glucose

levels and reducing the risk of long-term complications. Advances in pharmacotherapy, including novel insulin formulations, oral hypoglycemic agents, and emerging antidiabetic drugs, have significantly improved disease management. However, the global burden of diabetes continues to rise, underscoring the need for increased awareness, preventive strategies, and accessible healthcare services.

Given its complex etiology, progressive nature, and systemic impact, diabetes mellitus remains a major public health challenge, necessitating multidisciplinary approaches in research, prevention, and management. Understanding its pathophysiology, epidemiology, and treatment strategies is essential for developing effective interventions and improving patient outcomes.

2. Types of Diabetes Mellitus

Diabetes mellitus (DM) is a group of metabolic disorders characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. DM can be classified into the following major types:

2.1 Type 1 Diabetes Mellitus (T1DM):

Type 1 DM is an autoimmune disorder in which the body's immune system attacks and destroys the insulin-producing β-cells in the pancreas. This leads to an absolute insulin deficiency. It commonly manifests in childhood or adolescence but can occur at any age. Patients typically present with symptoms such as polyuria, polydipsia, polyphagia, and unexplained weight loss. Lifelong insulin therapy is required to maintain glucose homeostasis. Genetic susceptibility, environmental triggers, and immune system dysregulation play a crucial role in its pathogenesis.

2.2 Type 2 Diabetes Mellitus (T2DM):

Type 2 DM is the most prevalent form of diabetes, accounting for approximately 90–95% of all cases. It is primarily characterized by **insulin resistance**, where body tissues (mainly muscle, fat, and liver) fail to respond adequately to insulin, and **progressive β-cell dysfunction**, leading to relative insulin deficiency over time. Unlike T1DM, T2DM is strongly associated with obesity, sedentary lifestyle, unhealthy diet, and aging. Genetic factors also significantly contribute to susceptibility. Patients with T2DM may remain asymptomatic for years, and hyperglycemia is often detected during routine health checks. Chronic hyperglycemia in T2DM can lead to long-term complications, including cardiovascular disease, neuropathy, nephropathy, and retinopathy. Management involves lifestyle modifications (diet, exercise), oral hypoglycemic agents, and sometimes insulin therapy. Early diagnosis and intervention are crucial to prevent complications.

2.3 Gestational Diabetes Mellitus (GDM):

Gestational diabetes occurs when hyperglycemia is first recognized during pregnancy. It usually develops due to increased insulin resistance caused by pregnancy hormones. Most cases resolve after delivery, but women with GDM are at higher risk of developing T2DM later in life. GDM can increase the risk of complications such as macrosomia, birth trauma, and neonatal hypoglycemia.

2.4 Other Specific Types:

This category includes diabetes resulting from:

- **Genetic defects** (e.g., MODY – Maturity-Onset Diabetes of the Young)
- **Diseases of the pancreas** (e.g., pancreatitis, cystic fibrosis)
- **Endocrine disorders** (e.g., Cushing's syndrome, acromegaly)
- **Drug-induced diabetes** (e.g., corticosteroids, thiazides)



Figure 1 : Classification of Diabetes Mellitus

3. Pathophysiology of Diabetes Mellitus

Diabetes mellitus (DM) is a metabolic disorder primarily characterized by **chronic hyperglycaemia**, resulting from defects in insulin secretion, insulin action, or both. The pathophysiology differs among the types of diabetes but converges on impaired glucose homeostasis and the development of long-term complications.

3.1 General Mechanisms:

The fundamental metabolic abnormalities in DM include:

- **Impaired glucose utilization:** Peripheral tissues, especially skeletal muscle and adipose tissue, show decreased uptake and utilization of glucose due to insulin deficiency or resistance.
- **Increased hepatic glucose production:** The liver continues to produce glucose via glycogenolysis and gluconeogenesis despite elevated blood glucose levels, exacerbating hyperglycemia.
- **Dysregulation of lipid metabolism:** Insulin deficiency or resistance increases lipolysis, leading to elevated free fatty acids, which further impair insulin action.
- **Chronic hyperglycemia:** Sustained high blood glucose promotes oxidative stress, inflammation, and the formation of **advanced glycation end-products (AGEs)**, which contribute to vascular and neural complications.

3.2 Pathophysiology of Type 1 Diabetes Mellitus (T1DM):

T1DM is an **autoimmune disorder** in which autoreactive T-cells destroy pancreatic β-cells. This results in:

- **Absolute insulin deficiency:** Complete loss of endogenous insulin secretion leads to uncontrolled hepatic glucose production and impaired glucose uptake in peripheral tissues.
- **Metabolic consequences:** Without insulin, the body shifts to catabolism of fats and proteins for energy, causing **ketone body formation** and risk of diabetic ketoacidosis (DKA).
- **Autoimmunity triggers:** Genetic predisposition (HLA alleles), environmental factors (viruses, toxins), and immune dysregulation contribute to β-cell destruction.



Figure 2 : Pathophysiology of Type 1 vs Type 2 Diabetes

3.3 Pathophysiology of Type 2 Diabetes Mellitus (T2DM):

T2DM is characterized by **insulin resistance** and **progressive β-cell dysfunction**:

- **Insulin resistance:** Skeletal muscle, liver, and adipose tissues show reduced responsiveness to insulin. In muscles, glucose uptake is impaired; in the liver, insulin fails to suppress gluconeogenesis.
- **β-cell dysfunction:** Over time, pancreatic β-cells cannot compensate for insulin resistance, leading to relative insulin deficiency and hyperglycemia.
- **Contribution of adipokines and inflammation:** Obesity and visceral fat produce adipokines and pro-inflammatory cytokines that worsen insulin resistance.
- **Chronic metabolic stress:** Glucotoxicity, lipotoxicity, and oxidative stress damage β-cells further, perpetuating hyperglycemia.

3.4 Complications due to Chronic Hyperglycaemia:

Persistent elevated blood glucose leads to:

- **Oxidative stress:** Excess reactive oxygen species (ROS) damage endothelial cells and neurons.
- **Formation of AGEs:** AGEs cross-link proteins, altering vascular elasticity and promoting inflammation.
- **Microvascular complications:** Damage to small blood vessels causes **retinopathy, nephropathy, and neuropathy**.
- **Macrovascular complications:** Accelerated atherosclerosis increases the risk of **cardiovascular disease, stroke, and peripheral artery disease**.

3.5 Gestational Diabetes Mellitus (GDM) Pathophysiology:

GDM arises from **insulin resistance induced by placental hormones** (e.g., human placental lactogen, cortisol, and progesterone), which reduces maternal glucose uptake. In genetically or metabolically susceptible women, β-cells fail to compensate adequately, resulting in hyperglycemia during pregnancy.

4. Signs and Symptoms of Diabetes Mellitus

The clinical presentation of diabetes mellitus (DM) is primarily related to **hyperglycemia** and its metabolic consequences. While some patients, especially with type 2 diabetes, may remain asymptomatic in early stages, the classical features are often grouped as follows:

4.1 Polyuria, Polydipsia, and Polyphagia (The "Three Ps"):

- **Polyuria (excessive urination):** Elevated blood glucose levels exceed the renal threshold, leading to glucose excretion in urine (glycosuria). This osmotic effect draws water along, causing increased urine output.
- **Polydipsia (excessive thirst):** Fluid loss via polyuria triggers dehydration, stimulating thirst centers in the hypothalamus.
- **Polyphagia (increased hunger):** Despite hyperglycemia, tissues are unable to utilize glucose effectively due to insulin deficiency or resistance, prompting increased appetite.

4.2 Fatigue and Weight Loss:

- Insufficient glucose uptake by muscle and adipose tissue reduces energy availability, leading to persistent **fatigue**.
- In type 1 DM, **uncontrolled catabolism** of fats and proteins contributes to **weight loss**, even in the presence of normal or increased appetite.
- In type 2 DM, weight loss is less pronounced initially but may occur with prolonged hyperglycemia or poor glycemic control.

4.3 Blurred Vision:

- Hyperglycemia induces osmotic changes in the lens of the eye, causing temporary **blurred vision**.
- Chronic uncontrolled diabetes may lead to diabetic retinopathy, a microvascular complication that can permanently impair vision.

4.4 Delayed Wound Healing:

- High blood glucose impairs leukocyte function, collagen synthesis, and microcirculation, leading to **slow healing of cuts, ulcers, and surgical wounds**.

4.5 Recurrent Infections:

- DM increases susceptibility to infections due to impaired immune response. Common infections include:
  - **Urinary tract infections (UTIs)**
  - **Fungal infections** (e.g., candidiasis)
  - **Skin and soft tissue infections**

5. Diagnosis of Diabetes Mellitus

Diagnosis of diabetes mellitus (DM) relies on assessing blood glucose levels, hemoglobin A1c, and glucose tolerance. Early and accurate diagnosis is crucial to prevent complications. The commonly used diagnostic methods are:

5.1 Fasting Plasma Glucose (FPG):

- Measures blood glucose after an overnight fast of at least 8 hours.
- **Normal:** Less than 100 mg/dL
- **Prediabetes (impaired fasting glucose):** 100–125 mg/dL

- **Diabetes:** 126 mg/dL or higher on two separate occasions

5.2 Glycated Hemoglobin (HbA1c):

- Reflects average blood glucose levels over the past 2–3 months.
- **Normal:** Less than 5.7%
- **Prediabetes:** 5.7–6.4%
- **Diabetes:** 6.5% or higher

5.3 Oral Glucose Tolerance Test (OGTT, 2-hour post-glucose load):

- Measures plasma glucose 2 hours after ingestion of 75 g of glucose dissolved in water.
- **Normal:** Less than 140 mg/dL
- **Prediabetes (impaired glucose tolerance):** 140–199 mg/dL
- **Diabetes:** 200 mg/dL or higher

5.4 Continuous Glucose Monitoring (CGM) and Self-Monitoring of Blood Glucose (SMBG):

- CGM provides real-time glucose readings throughout the day and night, helping to assess glycemic patterns, fluctuations, and hypoglycemic episodes.
- SMBG allows patients to monitor daily glucose levels at home using finger-prick blood tests.
- Both methods are increasingly used to guide therapy, optimize glycemic control, and reduce the risk of acute and chronic complications.
- Query successful

Table 1: Diagnostic Criteria for Diabetes Mellitus

Diagnostic Test	Normal	Prediabetes	Diabetes
Hemoglobin A1c (HbA1c)	<5.7%	5.7%–6.4%	≥6.5%
Fasting Plasma Glucose (FPG)	<100 mg/dL (<5.6 mmol/L)	100–125 mg/dL (5.6–6.9 mmol/L)	≥126 mg/dL (≥7.0 mmol/L)*
Oral Glucose Tolerance Test (OGTT) 2-hour value	<140 mg/dL (<7.8 mmol/L)	140–199 mg/dL (7.8–11.0 mmol/L)	≥200 mg/dL (≥11.1 mmol/L)*
Random Plasma Glucose (RPG)	N/A	N/A	≥200 mg/dL (≥11.1 mmol/L)**

6. Management and Treatment of Diabetes Mellitus

Effective management of diabetes mellitus (DM) aims to achieve **glycemic control, prevent acute complications, and reduce the risk of long-term microvascular and macrovascular complications**. Management involves **non-pharmacological approaches** as the first-line strategy, followed by **pharmacological interventions** when necessary.

6.1 Non-Pharmacological Management

1. Dietary Modification:

- Adopting a **low-glycemic index diet** helps regulate postprandial blood glucose levels.
- Emphasis is placed on whole grains, vegetables, fruits with controlled portions, lean proteins, and healthy fats, while minimizing refined sugars and processed foods.
- Proper meal planning contributes to weight management and improved insulin sensitivity.

2. Physical Activity:

- Regular **aerobic exercise** for 30–45 minutes daily improves glucose uptake by muscles and enhances insulin sensitivity.
- Resistance training further supports muscle mass preservation and metabolic health.
- Physical activity also helps reduce cardiovascular risk factors associated with diabetes.

3. Weight Control and Stress Management:

- Achieving and maintaining a healthy weight improves insulin sensitivity and glycemic control, particularly in type 2 DM.
- Stress management through techniques such as meditation, yoga, or counseling can reduce hyperglycemia mediated by stress hormones (e.g., cortisol).



Figure 3 : Management and Treatment of Diabetes Mellitus

6.2 B. Pharmacological Management

Pharmacotherapy is introduced when lifestyle modifications alone are insufficient to maintain target glycemic levels. The choice of drug depends on **type of diabetes, patient comorbidities, and risk of hypoglycemia**. Common drug classes include:

1. Biguanides (e.g., Metformin):

- Mechanism: Reduces hepatic glucose production (gluconeogenesis) and improves peripheral insulin sensitivity.
- Often first-line therapy in type 2 DM due to efficacy, safety, and cardiovascular benefits.

2. Sulfonylureas (e.g., Glimepiride, Glibenclamide):

- Mechanism: Stimulate pancreatic β-cells to secrete more insulin.
- Effective in lowering blood glucose but carry a risk of hypoglycemia and weight gain.

3. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (e.g., Sitagliptin, Linagliptin):

- Mechanism: Prolong the activity of incretin hormones, enhancing glucose-dependent insulin secretion and suppressing glucagon release.

4. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors (e.g., Empagliflozin, Dapagliflozin):

- Mechanism: Promote renal excretion of glucose by inhibiting SGLT2 in the proximal tubules.
- Provide additional benefits, including weight loss and reduced cardiovascular risk.

5. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (e.g., Liraglutide, Exenatide):

- Mechanism: Enhance glucose-dependent insulin secretion, slow gastric emptying, and reduce appetite.
- Useful for weight reduction and improving glycemic control in type 2 DM.

6. Insulin Therapy (e.g., Regular, Lispro, Glargine):

- Mechanism: Replaces or supplements endogenous insulin in patients with type 1 DM or advanced type 2 DM.
- Various preparations allow flexibility in achieving basal and prandial glycemic control.

Table 2: Pharmacological Management of Diabetes

Drug Class	Example Drugs	Mechanism of Action (MOA)
Biguanides	Metformin	Decreases hepatic glucose production; improves insulin sensitivity in peripheral tissues (e.g., muscle).
Sulfonylureas	Glipizide, Glimepiride	Stimulate insulin secretion from pancreatic β-cells (insulin secretagogues), regardless of plasma glucose levels.
DPP-4 Inhibitors (Gliptins)	Sitagliptin, Saxagliptin	Prevent the breakdown of GLP-1 and GIP, thereby prolonging their action to increase insulin secretion and decrease glucagon.

SGLT2 Inhibitors (Gliflozins)	Empagliflozin, Dapagliflozin	Block the sodium-glucose co-transporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.
GLP-1 Receptor Agonists (Incretin mimetics)	Liraglutide, Semaglutide	Mimic endogenous GLP-1; enhance glucose-dependent insulin secretion, suppress glucagon secretion, slow gastric emptying, and promote satiety.
Insulin	Glargine (long-acting), Lispro (rapid-acting)	Replaces endogenous insulin; allows glucose uptake by cells, suppresses hepatic glucose production.

7. Complications of Diabetes Mellitus

Diabetes mellitus (DM), particularly when poorly controlled, leads to a range of **acute and chronic complications** affecting multiple organ systems. These complications are broadly categorized into **microvascular, macrovascular, and other complications**.

7.1 Microvascular Complications

These result from **damage to small blood vessels** due to chronic hyperglycemia, oxidative stress, and formation of advanced glycation end-products (AGEs):

1. **Diabetic Retinopathy:**
   - Damage to retinal blood vessels can lead to vision impairment and, in severe cases, blindness.
   - Early stages are often asymptomatic, emphasizing the importance of routine eye examinations.
2. **Diabetic Nephropathy:**
   - Chronic hyperglycemia and hypertension damage glomeruli, resulting in proteinuria and progressive renal failure.
   - Diabetic nephropathy is a leading cause of end-stage renal disease.
3. **Diabetic Neuropathy:**
   - Hyperglycemia-induced nerve damage can affect sensory, motor, and autonomic nerves.
   - Common symptoms include numbness, tingling, burning sensations, and loss of pain perception, increasing the risk of injuries.

7.2 Macrovascular Complications

These involve **large blood vessels**, increasing the risk of cardiovascular morbidity and mortality:

1. **Coronary Artery Disease (CAD):** Accelerated atherosclerosis increases the risk of angina, myocardial infarction, and heart failure.
2. **Stroke (Cerebrovascular Disease):** Hyperglycemia and vascular damage predispose patients to ischemic and, less commonly, hemorrhagic strokes.
3. **Peripheral Vascular Disease (PVD):** Reduced blood flow to the limbs can cause claudication, non-healing ulcers, and may necessitate amputation in severe cases.

C. Other Complications

1. **Diabetic Foot Ulcers:**

- Combined effects of neuropathy, poor circulation, and impaired wound healing increase the risk of foot ulcers and infections.

2. **Infections:**

- Immune dysfunction in diabetes makes patients more susceptible to bacterial, fungal, and viral infections.

3. **Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycaemic State (HHS):**

- Acute life-threatening metabolic emergencies more common in type 1 DM (DKA) and type 2 DM (HHS), characterized by severe hyperglycemia, dehydration, and electrolyte imbalances

8. Recent Advances in Diabetes Management

Recent advances in diabetes mellitus (DM) focus on improving glycemic control, enhancing patient compliance, and targeting underlying pathophysiology. Innovative technologies and therapeutic strategies are transforming diabetes care beyond conventional lifestyle and pharmacological approaches.

8.1 Artificial Pancreas Systems

- These systems integrate continuous glucose monitors (CGMs) with insulin pumps, creating a closed-loop system.
- Real-time glucose readings allow automatic insulin delivery, minimizing hyperglycemia and hypoglycemia episodes.
- Artificial pancreas systems improve glycemic control and reduce the burden of frequent self-monitoring.

8.2 Gene Editing for β-Cell Regeneration

- **CRISPR-Cas9 technology** is being explored to modify genes responsible for β-cell development and survival.
- This approach aims to regenerate functional pancreatic β-cell**s**, potentially offering a curative strategy for type 1 diabetes.

8.3 Nanocarrier-Based Insulin Delivery

- Nanoparticles and liposomes are being used to enhance insulin stability and bioavailability**.**
- These carriers enable controlled, targeted, and sometimes non-invasive insulin delivery (e.g., oral or inhalational routes), reducing the need for frequent injections.

8.4 Stem Cell Therapy for β-Cell Replacement

- Stem cells can be differentiated into insulin-producing β-like cells for transplantation.
- This approach offers a potential long-term solution for insulin deficiency in type 1 diabetes.
- Current research focuses on improving cell survival, integration, and immune protection post-transplantation.

8.5 Smart Insulin Patches

- These wearable patches combine microneedles with glucose-sensing technology to release insulin in response to rising blood glucose levels.
- They provide a non-invasive, responsive insulin delivery system, improving patient comfort and glycemic control.

9. Conclusion

Diabetes mellitus remains a major global health concern, affecting millions worldwide and contributing significantly to morbidity and mortality due to its acute and chronic complications. Effective management requires a comprehensive and multidisciplinary approach, including early detection, regular monitoring, patient education, lifestyle modifications, and tailored pharmacological interventions. Advances in technology, such as continuous glucose monitoring, artificial pancreas systems, and smart insulin delivery devices, have significantly improved glycemic control and patient quality of life. Meanwhile, emerging therapeutic strategies, including gene editing, stem cell therapy, and nanocarrier-based insulin delivery, hold promise for restoring pancreatic β-cell function and achieving long-term remission, particularly in type 1 diabetes. Personalized medicine approaches, guided by genetic, metabolic, and behavioral profiling, are expected to optimize treatment regimens and minimize complications. Despite these advancements, challenges remain in ensuring accessibility, affordability, and adherence to therapy across diverse populations. Continued research, innovation, and public health initiatives are essential to mitigate the burden of diabetes, reduce its associated complications, and move toward a future where precise, individualized, and curative strategies can transform diabetes care on a global scale.

10. References

1) Patel DK, Kumar R, Prasad SK, Hemalatha S. Pedalium murex Linn (Pedaliaceae) fruits: A comparative antioxidant activity of its different fractions. Asian Pac J Trop Biomed. 2011;1:395–400. doi: 10.1016/S2221-1691(11)60087-7.
2) Jung HA, Islam MD, Kwon YS, Jin SE, Son YK, Park JJ, et al. Extraction and identification of three major aldose reductase inhibitors from Artemisia montana. Food Chem Toxicol. 2011;49:376–384. doi: 10.1016/j.fct.2010.11.012.
3) Warjeet Singh L. Traditional medicinal plants of Manipur as anti-diabetics. J Med Plants Res. 2011;5:677–687.
4) Meenakshi P, Bhuvaneshwari R, Rathi MA, Thirumoorthi L, Guravaiah DC, Jiji MJ, et al. Antidiabetic activity of ethanolic extract of Zaleya decandra in alloxan-induced diabetic rats. Appl Biochem Biotechnol. 2010;162:1153–1159. doi: 10.1007/s12010-009-8871-x.
5) Balaraman AK, Singh J, Dash S, Maity TK. Antihyperglycemic and hypolipidemic effects of Melothria maderaspatana and Coccinia indica in Streptozotocin induced diabetes in rats. Saudi Pharm J. 2010;18:173–178. doi: 10.1016/j.jsps.2010.05.009.
6) Fröde TS, Medeiros YS. Animal models to test drugs with potential antidiabetic activity. J Ethnopharmacol. 2008;115:173–183. doi: 10.1016/j.jep.2007.10.038.
7) Dewanjee S, Das AK, Sahu R, Gangopadhyay M. Antidiabetic activity of Diospyros peregrina fruit: effect on hyperglycemia, hyperlipidemia and augmented oxidative stress in experimental type 2 diabetes. Food Chem Toxicol. 2009;47:2679–2685. doi: 10.1016/j.fct.2009.07.038. [DOI] [PubMed] [Google Scholar]
8) Bagri P, Ali M, Aeri V, Bhowmik M, Sultana S. Antidiabetic effect of Punica granatum flowers: Effect on hyperlipidemia, pancreatic cells lipid peroxidation and antioxidant enzymes in experimental diabetes. Food Chem Toxicol. 2009;47:50–54. doi: 10.1016/j.fct.2008.09.058.
9) Ding Z, Lu Y, Lu Z, Lv F, Wang Y, Bie Y, et al. Hypoglycaemic effect of comatin, an antidiabetic substance separated from Coprinus comatus broth, on alloxan-induced-diabetic rats. Food Chem. 2010;121:39–43.

10) Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: An overview. Indian J Med Res. 2007;125:451–472.
11) Venkatesh S, Madhava Reddy B, Dayanand Reddy G, Mullangi R, Lakshman M. Antihyperglycemic and hypolipidemic effects of Helicteres isora roots in alloxan-induced diabetic rats: A possible mechanism of action. J Nat Med. 2010;64:295–304. doi: 10.1007/s11418-010-0406-9.
12) Modak M, Dixit P, Londhe J, Ghaskadbi S, Paul A, Devasagayam T. Indian herbs and herbal drugs used for the treatment of diabetes. J Clin Biochem Nutr. 2007;40:163–173. doi: 10.3164/jcbn.40.163.
13) Feshani AM, Kouhsari SM, Mohammadi S. Vaccinium arctostaphylos, a common herbal medicine in Iran: molecular and biochemical study of its antidiabetic effects on alloxan-diabetic Wistar rats. J Ethnopharmacol. 2011;133:67–74. doi: 10.1016/j.jep.2010.09.002.
14) Patel DK, Kumar R, Laloo D, Hemalatha S. Evaluation of phytochemical and antioxidant activities of the different fractions of Hybanthus enneaspermus (Linn.) F. Muell. (Violaceae) Asian Pac J Trop Med. 2011;4:391–396. doi: 10.1016/S1995-7645(11)60110-7.
15) Bnouham M, Ziyyat A, Mekhfi H, Tahri A, Legssyer A. Medicinal plants with potential antidiabetic activity - A review of ten years of herbal medicine research (1990–2000) Int J Diabetes Metab. 2006;14:1–25.
16) Patil RN, Patil RY, Ahirwar A, Ahirwar D. Evaluation of antidiabetic and related actions of some Indian medicinal plants in diabetic rats. Asian Pac J Trop Med. 2011;4:20–23. doi: 10.1016/S1995-7645(11)60025-4.
17) Geetha G, Kalavalarasariel Gopinathapillai P, Sankar V. Anti diabetic effect of Achyranthes rubrofusca leaf extracts on alloxan induced diabetic rats. Pak J Pharm Sci. 2011;24:193–199.
18) Ravikumar R, Krishnamoorthy P, Kalidoss A. Antidiabetic and antioxidant efficacy of Andrographis paniculata in alloxanized albino rats. Int J Pharm Technol. 2010;2:1016–1027.
19) Biradar SM, Rangani AT, Kulkarni VH, Joshi H, Habbu PV, Smita DM. Prevention of onset of hyperglycemia by extracts of Argyriea cuneata on alloxan-induced diabetic rats. J Pharm Res. 2010;3:2186–2187.
20) Dheer R, Bhatnagar P. A study of the antidiabetic activity of Barleria prionitis Linn. Indian J Pharmacol. 2010;42:70–73. doi: 10.4103/0253-7613.64493.
21) Rathee S, Mogla OP, Sardana S, Vats M, Rathee P. Antidiabetic activity of Capparis decidua Forsk Edgew. J Pharm Res. 2010;3:231–234.
22) Lodha SR, Joshi SV, Vyas BA, Upadhye MC, Kirve MS, Salunke SS, et al. Assessment of the antidiabetic potential of Cassia grandis using an in vivo model. J Adv Pharm Technol Res. 2010;1:330–333. doi: 10.4103/0110-5558.72429.
23) Nabeel MA, Kathiresan K, Manivannan S. Antidiabetic activity of the mangrove species Ceriops decandra in alloxan-induced diabetic rats. J Diabetes. 2010;2:97–103. doi: 10.1111/j.1753-0407.2010.00068.x.
24) Kumawat NS, Chaudhari SP, Wani NS, Deshmukh TA, Patil VR. Antidiabetic activity of ethanol extract of Colocasia esculenta leaves in alloxan induced diabetic rats. Int J Pharm Tech Res. 2010;2:1246–1249.